Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
- Authors: Vikulova OK1, Zuraeva ZT1, Michaleva OV1, Nikankina LV1, Shamkhalova MS.1, Shestakova MV1, Dedov II1
-
Affiliations:
- Endocrinology Research Centre, Ministry of Health of the Russia
- Issue: Vol 90, No 6 (2018)
- Pages: 59-64
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32775
- DOI: https://doi.org/10.26442/terarkh201890659-64
- ID: 32775
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
O K Vikulova
Endocrinology Research Centre, Ministry of Health of the Russia
Email: olga-vikulova-1973@yandex.ru
к.м.н., зав. отд-нием эпидемиологии и государственного регистра сахарного диабета, ведущий научный сотрудник НМИЦ эндокринологии; тел.: +7(495)668-20-77; e-mail: olga-vikulova-1973@yandex.ru; ORCID: 0000-0003-0571-8882 Moscow, Russia
Z T Zuraeva
Endocrinology Research Centre, Ministry of Health of the Russiaн.с. НМИЦ эндокринологии Moscow, Russia
O V Michaleva
Endocrinology Research Centre, Ministry of Health of the Russiaаспирант НМИЦ эндокринологии Moscow, Russia
L V Nikankina
Endocrinology Research Centre, Ministry of Health of the Russiaк.м.н., в.н.с. клинико-диагностической лаборатории НМИЦ эндокринологии Moscow, Russia
M Sh Shamkhalova
Endocrinology Research Centre, Ministry of Health of the Russiaд.м.н., зав. отд-нием диабетической болезни почек и посттрансплантационной реабилитации НМИЦ эндокринологии Moscow, Russia
M V Shestakova
Endocrinology Research Centre, Ministry of Health of the Russiaакадемик РАН, д.м.н., проф., зам. директора Центра по научной работе, директор Института диабета НМИЦ эндокринологии Moscow, Russia
I I Dedov
Endocrinology Research Centre, Ministry of Health of the Russiaакадемик РАН, д.м.н., проф., директор НМИЦ эндокринологии, член президиума РАН, президент Российской ассоциации эндокринологов, главный внештатный специалист-эксперт эндокринолог Минздрава России Moscow, Russia
References
- IDF. IDF Diabetes Atlas; 2018. 10.1289/image.ehp.v119.i03' target='_blank'>https://doi: 10.1289/image.ehp.v119.i03
- Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико - статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;20(1):13-41. doi: 10.14341/DM8664
- Alicic R.Z, Rooney M.T, Tuttle K.R. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;7;12(12):2032-45. doi: 10.2215/CJN.11491116
- Salvador J, Andrada P. Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes. Med Clin (Barc). 2014;143 Suppl 2:28-34. doi: 10.1016/S0025-7753(14)70106-X
- Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014;23(1):54-60. doi: 10.1097/01.mnh.0000437542.77175.a
- Шестакова М.В., Викулова О.К. Инновации в диагностике и лечении сахарного диабета 2 типа. Врач. 2012;(8):2-6.
- Лебедева Н.О., Викулова О.К. Маркеры доклинической диагностики диабетической нефропатии у пациентов с сахарным диабетом 1 типа. Сахарный диабет. 2012;(2):38-45. doi: 10.14341/2072-0351-5517
- Gemma C, Gerard M, Christian D. Biomarkers in diabetic nephropathy: Present and future. World J Diabetes. 2014;15;5(6):763-76. doi: 10.4239/wjd.v5.i6.763
- Hocher B, Reichetzeder C, Alter M.L. Renal and cardiac effects of DPP-4 inhibitors - from preclinical development to clinical research. Kidney Blood Press Res. 2012;36(1):65-84. doi: 10.1159/000339028
- Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin - induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 2012;61(10):1422-34. doi: 10.1016/j.metabol.2012.03.002
- Chang J.T, Liang Y.J, Hsu C.Y, Chen C.Y, Chen P.J, Yang Y.F, Chen Y.L, Pei D, Chang J.B, Leu J.G. Glucagon - like peptide receptor agonists attenuate advanced glycation end products - induced inflammation in rat mesangial cells. BMC Pharmacol Toxicol. 2017;24;18(1):67. doi: 10.1186/s40360-017-0172-3
- Mima A, Hiraoka-Yamomoto J, Li Q, et al. Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC b Activation in Diabetes. Diabetes. 2012;61(11):2967-79. doi: 10.2337/db11-1824
- Zhang H, Zhang X, Hu C, Lu W. Exenatide Reduces Urinary Transforming Growth Factor-ß1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria. Kidney Blood Press Res. 2012;35(6):483-8. doi: 10.1159/000337929
- Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi S.I. Glucagon - like peptide-1 suppresses advanced glycation end product - induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 2011;60(9):1271-7. doi: 10.1016/j.metabol.2011.01.010
- Zeni L, Norden A.G.W, Cancarini G, Unwin R.J. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017;30(6):701-17. doi: 10.1007/s40620-017-0423-9
- Lou N.J, Ni Y.H, Jia H.Y, Deng J.T, Jiang L, Zheng F.J, Sun A.L. Urinary Microvesicle-Bound Uromodulin: A Potential Molecular Biomarker in Diabetic. Kidney Dis. 2017;2017:3918681. doi: 10.1155/2017/ 3918681
- Zobel E.H, von Scholten B.J, Lindhardt M, Persson F, Hansen T.W, Rossing P. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. J Diabetes Complications. 2017;31(1):162-8. doi: 10.1016/j.jdiacomp.2016. 09.016
- Mundel P. Podocytes and the quest for precision medicines for kidney diseases. Pflugers Arch. 2017;469(7-8):1029-37. doi: 10.1007/s00424-017-2015-x
- Gordin D, Forsblom C, Panduru N.M, Thomas M.C, Bjerre M, Soro-Paavonen A, Tolonen N, Sandholm N, Flyvbjerg A, Harjutsalo V, Groop P.H; Finn Diane Study Group. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardio - vascular disease, and all - cause mortality in patients with type 1 diabetes. Diabetes Care. 2014;37(9):2593-600. doi: 10.2337/dc14-0065
- Marso S.P, Daniels G.H, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056/NEJMoa1603827
![](/img/style/loading.gif)